Why lung cancer doesn't respond well to immunotherapy

by Anne Trafton,Massachusetts Institute of TechnologyA new MIT study explains why dendritic cells (green) in lymph nodes that drain from the lungs fail to stimulate killer T cells (white) to att

Updated on: January 08,2024

Why lung cancer doesn't respond well to immunotherapy

by Anne Trafton,Massachusetts Institute of TechnologyA new MIT study explains why dendritic cells (green) in lymph nodes that drain from the lungs fail to stimulate killer T cells (white) to att

Updated on:January 08,2024

Black/white breast cancer subtype incidence in men differs from trends in women

byAmerican Cancer SocietyCredit: CC0 Public DomainIncidence rates for hormone receptor positive (HR+) breast cancers are considerably higher in black men than white men, in stark contrast to low

Updated on: December 22,2023

Black/white breast cancer subtype incidence in men differs from trends in women

byAmerican Cancer SocietyCredit: CC0 Public DomainIncidence rates for hormone receptor positive (HR+) breast cancers are considerably higher in black men than white men, in stark contrast to low

Updated on:December 22,2023

Unraveling of genetic mechanism behind tumor formation may improve targeted treatment for cancer patients

by Rutgers Cancer Institute of New JerseyCredit: Pixabay/CC0 Public DomainGenetic alterations in the FGFR2 gene occur in various cancer types and represent a promising target for therapies. However, c

Updated on: December 18,2023

Unraveling of genetic mechanism behind tumor formation may improve targeted treatment for cancer patients

by Rutgers Cancer Institute of New JerseyCredit: Pixabay/CC0 Public DomainGenetic alterations in the FGFR2 gene occur in various cancer types and represent a promising target for therapies. However, c

Updated on:December 18,2023

Deep Learning in Cancer: Redefining Diagnosis, Prognosis, and Precision Oncology

Updated on: May 28,2025

Deep Learning in Cancer: Redefining Diagnosis, Prognosis, and Precision Oncology

Updated on:May 28,2025

Using the immune system to fight cancer: an interview with Dr Charles Akle

Why does cancer occur?We all produce as many as 100,000 different types of cancer cells every day, which are recognized and eliminated by our extraordinarily efficient immune system.However, if someth

Updated on: October 27,2023

Using the immune system to fight cancer: an interview with Dr Charles Akle

Why does cancer occur?We all produce as many as 100,000 different types of cancer cells every day, which are recognized and eliminated by our extraordinarily efficient immune system.However, if someth

Updated on:October 27,2023

Marker for therapy response in acute myeloid leukemia identified

byGerman Cancer Research CenterCell line sensitivity and additional patient data. A IC50s for VEN of 19 AML cell lines classified as primitive (Prim-AML, n = 11) or monocytic (Mono-AML, n = 8) t

Updated on: December 21,2023

Marker for therapy response in acute myeloid leukemia identified

byGerman Cancer Research CenterCell line sensitivity and additional patient data. A IC50s for VEN of 19 AML cell lines classified as primitive (Prim-AML, n = 11) or monocytic (Mono-AML, n = 8) t

Updated on:December 21,2023

Discovery of small molecule Gαq/11 protein inhibitors against uveal melanoma

by Compuscript LtdGraphical abstract:Constitutively activated Gαq/11 proteins drive the vast majority of uveal melanoma (UM). GQ262 effectively combats UM both in vitro and in vivo by targeting Gαq/11

Updated on: December 21,2023

Discovery of small molecule Gαq/11 protein inhibitors against uveal melanoma

by Compuscript LtdGraphical abstract:Constitutively activated Gαq/11 proteins drive the vast majority of uveal melanoma (UM). GQ262 effectively combats UM both in vitro and in vivo by targeting Gαq/11

Updated on:December 21,2023

Newfound mechanism suggests drug combination could starve pancreatic cancer

byNYU Langone HealthPancreatic cancer cells (blue) growing as a sphere encased in membranes (red). Credit: National Cancer InstituteA new combination of treatments safely decreased growth of pan

Updated on: October 14,2023

Newfound mechanism suggests drug combination could starve pancreatic cancer

byNYU Langone HealthPancreatic cancer cells (blue) growing as a sphere encased in membranes (red). Credit: National Cancer InstituteA new combination of treatments safely decreased growth of pan

Updated on:October 14,2023

Leukemia vulnerability discovered causing drug sensitivity

byJosep Carreras Leukaemia Research InstituteCells from acute lymphoblastic leukemia, a disease against which treatment with glutathione inhibitors has demonstrated preclinical efficacy, dying b

Updated on: December 22,2023

Leukemia vulnerability discovered causing drug sensitivity

byJosep Carreras Leukaemia Research InstituteCells from acute lymphoblastic leukemia, a disease against which treatment with glutathione inhibitors has demonstrated preclinical efficacy, dying b

Updated on:December 22,2023

Larotrectinib in tumours with NTRK gene fusion: Data are not yet sufficient

byInstitute for Quality and Efficiency in Health CareCredit: Institute for Quality and Efficiency in Health CareIn the summer of 2019, larotrectinib was approved as the first drug in Europe to b

Updated on: December 20,2023

Larotrectinib in tumours with NTRK gene fusion: Data are not yet sufficient

byInstitute for Quality and Efficiency in Health CareCredit: Institute for Quality and Efficiency in Health CareIn the summer of 2019, larotrectinib was approved as the first drug in Europe to b

Updated on:December 20,2023

One-cycle cisplatin seems safe for high-risk early testicular cancer

(HealthDay)—For high-risk stage 1 nonseminoma germ cell tumors of the testis (NSGCTT), one cycle of adjuvant bleomycin, etoposide (500 mg/m²), and cisplatin (BE500P) is safe, resulting in a two-year m

Updated on: December 20,2023

One-cycle cisplatin seems safe for high-risk early testicular cancer

(HealthDay)—For high-risk stage 1 nonseminoma germ cell tumors of the testis (NSGCTT), one cycle of adjuvant bleomycin, etoposide (500 mg/m²), and cisplatin (BE500P) is safe, resulting in a two-year m

Updated on:December 20,2023

Patients prefer stool test to colonoscopy

byCedars-Sinai Medical CenterGraphical abstract. Credit:Clinical Gastroenterology and Hepatology(2022). DOI: 10.1016/j.cgh.2022.07.012Three-quarters of people prefer to do a fecal im

Updated on: December 19,2023

Patients prefer stool test to colonoscopy

byCedars-Sinai Medical CenterGraphical abstract. Credit:Clinical Gastroenterology and Hepatology(2022). DOI: 10.1016/j.cgh.2022.07.012Three-quarters of people prefer to do a fecal im

Updated on:December 19,2023